Search by Drug Name or NDC
NDC 00310-9500-01 TRUQAP 160 mg/1 Details
TRUQAP 160 mg/1
TRUQAP is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is CAPIVASERTIB.
MedlinePlus Drug Summary
Capivasertib is used in combination with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive (depends on hormones such as estrogen to grow) advanced breast cancer that has spread to nearby tissues or other parts of the body in adults whose cancer got worse during or after certain other treatments. Capivasertib is also used in combination with another medication and fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive advanced breast cancer that has spread to other parts of the body in women who have not experienced menopause (change of life; end of monthly menstrual periods) and in those who are close to or who have already experienced menopause. Capivasertib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Related Packages: 00310-9500-01Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Capivasertib
Product Information
| NDC | 00310-9500 |
|---|---|
| Product ID | 0310-9500_1f261e9d-095f-4472-85fc-690fc0e240cd |
| Associated GPIs | |
| GCN Sequence Number | 085520 |
| GCN Sequence Number Description | capivasertib TABLET 160 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 55025 |
| HICL Sequence Number | 049313 |
| HICL Sequence Number Description | CAPIVASERTIB |
| Brand/Generic | Brand |
| Proprietary Name | TRUQAP |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | capivasertib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 160 |
| Active Ingredient Units | mg/1 |
| Substance Name | CAPIVASERTIB |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA218197 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00310-9500-01 (00310950001)
| NDC Package Code | 0310-9500-01 |
|---|---|
| Billing NDC | 00310950001 |
| Package | 64 TABLET, FILM COATED in 1 BOTTLE (0310-9500-01) |
| Marketing Start Date | 2023-11-16 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |